All Stories
Follow
Subscribe to Marseille-Kliniken AG

Marseille-Kliniken AG

euro adhoc: Marseille-Kliniken AG
Quarterly or Semiannual Financial Statements
- Sales of EUR 102.4 million at previous year's level - 6% increase in earnings to EUR 5.2 million - For the first time positive signs from the Rehabilitation division

Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
08.02.2005
In the first half of the fiscal year 2004/05, the Marseille-Kliniken
AG (Prime Standard, ISIN DE 0007783003, MKA) was able to slightly
expand sales to EUR 102.4 million (previous year EUR 102.1 million).
The earnings pursuant to DVFA/SG (IFRS) were improved to EUR 5.2
million, up EUR 0.3 million from EUR 4.9 million. The earnings per
share came to EUR 0.43 following EUR 0.40 in the same period one year
ago.
The increases in sales and earnings were exclusively attributable to
the core division Nursing, which was able to further compensate for
the continuing downtrend in the Rehabilitation unit. The
Marseille-Kliniken AG provides more than three quarters of its total
bed capacity in the Nursing division and recorded sales of EUR 75.4
million during the period under review compared with EUR 72.8 million
in the period one year ago. The Nursing division improved the
earnings pursuant to DVFA/SG (IFRS) by EUR 1.1 million to EUR 6.9
million (previous year EUR 5.8 million). Due to reconstruction work
at the sites in Belzig and Leipzig the utilization rate in the
Nursing segment declined slightly to 93.8% from 94.5% in the previous
year. This means a decrease in the Group’s overall utilization rate
from 90.6% to currently 89.6%.
In the Rehabilitation segment sales remained EUR 2.1 million below
previous year’s level of EUR 28.2 million and amounted to EUR 26.1
million for the first half of the fiscal year 2004/05. Also the loss
pursuant to DVFA/SG (IFRS) amounting to EUR 1.7 million (previous
year loss of EUR 0.9 million) still had a negative impact on the
overall results. 
However, it should be noted that the restructuring measures are
starting to pay off. The utilization rate improved to currently 77.1%
in the usually seasonally weak 2nd quarter compared with 75.6% in the
1st quarter. If this trend will continue in the following quarters, a
gradual reduction in the burdens from the Rehabilitation division
should be expected.
Due to the sustained favorable trends in the Nursing division, the
management of Marseille-Kliniken AG expects an increase in the
consolidated sales and a disproportionately stronger improvement in
earnings in the fiscal year 2004/2005.
For further information please contact:
Marseille-Kliniken AG	
Axel Hölzer	
CEO
Alte Jakobstraße 79/80	
10709 Berlin	
Tel.: 030 / 246 32-400	
Fax: 030 / 246 32-401
end of announcement                    euro adhoc 08.02.2005 20:10:00 

Further inquiry note:

Christian Hillermann
c.hillermann@hillermann-consulting.de
+49 (0) 40-414069-13

Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: Prime Standard, CDAX, Classic All Share, Prime All Share
Börsen: Berliner Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Bremer Wertpapierbörse (BWB) / free trade
Hamburger Wertpapierbörse / official dealing
Frankfurter Wertpapierbörse / official dealing

Original content of: Marseille-Kliniken AG, transmitted by news aktuell

More stories: Marseille-Kliniken AG
More stories: Marseille-Kliniken AG